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Millions of persons worldwide, including 
13 million Americans (U.S. Environmental 
Protection Agency 2009) and > 50 million in 
Bangladesh (British Geological Survey 2007), 
have been chronically exposed to arsenic, a 
group 1 human carcinogen (International 
Agency for Research on Cancer 2004), 
through contaminated drinking water. Arsenic 
exposure from drinking water has been asso-
ciated with cardio vascular disease (CVD) 
(Chen CJ et al. 1996; Chen Y et al. 2011; 
Chiou et al. 1997; Liao et al. 2012; Tseng 
et al. 2003; Yuan et al. 2007). However, 
prospective studies assessing susceptibility to 
CVD due to arsenic exposure are rare.
Arsenic in drinking water is present as 
inorganic arsenic (iAS). Once ingested, iAs 
is methylated to monomethylarsonic acid 
(MMA) and dimethylarsinic acid (DMA). The 
relative distribution of urinary arsenic metab-
olites varies from person to person and has 
been interpreted to reflect arsenic methyla-
tion capacity (Hopenhayn-Rich et al. 1996; 
Vahter 1999). Mechanistic studies have shown 
that MMAIII is more toxic than iAs or any 
of the penta valent metabolites (Petrick et al. 
2000; Styblo et al. 2000). Incomplete methyla-
tion, indicated by a high percentage of urinary 
MMA (MMA%), has been consistently related 
to cancers (Chen YC et al. 2003; Pu et al. 
2007; Steinmaus et al. 2006; Yu et al. 2000), 
and there is some evidence of stronger asso-
ciations among smokers than nonsmokers (Pu 
et al. 2007; Steinmaus et al. 2006). However, 
the association between urinary MMA% and 
CVD risk is unknown, and research on the 
combined effects of arsenic and biomarkers of 
arsenic susceptibility on CVD risk is needed.
We conducted a prospective case–cohort 
study nested in a large prospective cohort to 
assess associations of arsenic exposure from 
drinking water and arsenic methyla tion capac-
ity, indicated using relative distribution of 
urinary arsenic metabolites, with CVD risk.
Materials and Methods
The parent Health Effects of Arsenic 
Longitudinal Study (HEALS). Details of the 
study methodologies have been presented else-
where (Ahsan et al. 2006). Briefly, between 
March and June 2000 (prior to recruitment), 
we collected water samples and geographic 
coordinates for 5,966 contiguous drinking-
water wells in a well-defined geographic area 
of 25 km2 in Araihazar, Bangladesh (Parvez 
et al. 2006). Between October 2000 and May 
2002, we recruited 11,746 men and women 
who were primary users of one of the tested 
wells, desig nated as the “index” well, for 
≥ 3 years. The response rate was 97.5% (Ahsan 
et al. 2006). Demographic and lifestyle data 
were collected using a standardized question-
naire. Trained clinicians measured blood pres-
sure with an automatic sphygmomanometer 
(Chen Y et al. 2007). The cohort continues 
to be actively followed every 2 years with in-
person visits that include a physical examina-
tion and collection of urine samples. For the 
present study, interim health surveys were 
conducted every 6 months between the bien-
nial follow-up visits. A field clinic was estab-
lished exclusively for the cohort participants 
to receive medical diagnoses and treatments 
and to facilitate follow-up (Ahsan et al. 2006). 
Informed consent was obtained from the study 
participants and the study procedures were 
approved by the ethical committee of the 
Bangladesh Medical Research Council and 
the institutional review boards of Columbia 
University and the University of Chicago.
Selection of the subcohort. The case–cohort 
design has been used to analyze cohort data 
efficiently when most observations are cen-
sored (nondiseased) at the end of follow-up 
(Prentice 1986). The case–cohort design has 
the advantage that the subcohort can be used 
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Background: Few prospective studies have evaluated the influence of arsenic methyla tion capacity 
on cardio vascular disease (CVD) risk.
oBjective: We evaluated the association of arsenic exposure from drinking water and arsenic 
methyla tion capacity with CVD risk.
Method: We conducted a case–cohort study of 369 incident fatal and nonfatal cases of CVD, includ-
ing 211 cases of heart disease and 148 cases of stroke, and a subcohort of 1,109 subjects randomly 
selected from the 11,224 participants in the Health Effects of Arsenic Longitudinal Study (HEALS).
results: The adjusted hazard ratios (aHRs) for all CVD, heart disease, and stroke in association 
with a 1-SD increase in baseline well-water arsenic (112 µg/L) were 1.15 (95% CI: 1.01, 1.30), 1.20 
(95% CI: 1.04, 1.38), and 1.08 (95% CI: 0.90, 1.30), respectively. aHRs for the second and third 
tertiles of percentage urinary monomethylarsonic acid (MMA%) relative to the lowest tertile, respec-
tively, were 1.27 (95% CI: 0.85, 1.90) and 1.55 (95% CI: 1.08, 2.23) for all CVD, and 1.65 (95% CI: 
1.05, 2.60) and 1.61 (95% CI: 1.04, 2.49) for heart disease specifically. The highest versus lowest ratio 
of urinary dimethylarsinic acid (DMA) to MMA was associated with a significantly decreased risk of 
CVD (aHR = 0.54; 95% CI: 0.34, 0.85) and heart disease (aHR = 0.54; 95% CI: 0.33, 0.88). There 
was no significant association between arsenic metabolite indices and stroke risk. The effects of incom-
plete arsenic methyla tion capacity—indicated by higher urinary MMA% or lower urinary DMA%—
with higher levels of well-water arsenic on heart disease risk were additive. There was some evidence of 
a synergy of incomplete methyla tion capacity with older age and cigarette smoking.
conclusions: Arsenic exposure from drinking water and the incomplete methyla tion capacity of 
arsenic were adversely associated with heart disease risk.
key words: arsenic, arsenic methyla tion capacity, Bangladesh, cardio vascular disease, case–cohort 
study.
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as controls for multiple different case groups 
arising from the cohort (Wacholder 1991). 
In addition, it preserves the ability of assess-
ing interaction on the additive scale between 
exposure and potential effect modifiers such 
as age and sex, which are often matched in 
nested case–control studies.
Data on well-water arsenic exposure levels 
were available for all cohort participants. From 
the 11,224 participants who gave urine sam-
ples at baseline (95.6% of all cohort members), 
a 10% random sample (n = 1,109) was selected 
as the subcohort.
Selection of the cases. Our outcome of 
interest was incident fatal and nonfatal cases of 
CVD coded to the International Classification 
of Diseases, 10th Revision [ICD-10; World 
Health Organization (WHO) 2007] (ICD-10 
codes I00–I99), including fatal and nonfatal 
stroke (codes I60–I69) and fatal and nonfa-
tal cases of heart disease, which occurred after 
baseline and before 18 March 2009 (the end 
of the third follow-up). We a priori included 
cases of ischemic heart disease and other heart 
disease in a combined category of heart dis-
ease (codes I20–I25 and I30–I52) (Chen Y 
et al. 2011). We adapted a validated verbal 
autopsy procedure that was developed by the 
International Centre for Diarrheal Disease 
Research, Bangladesh (ICDDR,B), in collabo-
ration with the WHO, to ascertain the cause 
of deaths in cohort participants (Chen Y et al. 
2011). The ICDDR,B has used this method 
to ascertain causes of deaths since 1971 
(Ronsmans et al. 1998) and has documented 
an overall 95% specificity and 50–80% sen-
sitivity for deaths due to CVD (Alam et al. 
2004). During the follow-up, upon receipt 
of a death report from family or neighbors, a 
study physician and a trained social worker 
administered the verbal autopsy form to the 
next of kin. Medical records and death certifi-
cates were collected for approximately 5% of 
deaths in the present study. An outcome assess-
ment committee, consisting of physicians and 
a consulting cardiologist and neurologist who 
were blinded to exposure status, reviewed these 
data monthly. Causes of deaths were coded 
according to the WHO classification (Aho 
et al. 1980) and the ICD-10 (WHO 2007).
For nonfatal stroke and ischemic heart dis-
ease, potential cases and participants with heart 
disease symptoms including high blood pres-
sure, chest pain, shortness of breath, irregular 
heartbeat, and/or palpitations were identified 
during our biennial follow-up visits, interim 
health surveys, or among individuals who came 
to the field clinic for medical treatment. An 
appointment at the field clinic was scheduled, 
and field staff visited the homes of participants 
who failed to report on the scheduled date in 
order to schedule a new appointment within 
2 weeks. Participants were referred to three 
trained physicians, who were blinded to arsenic 
exposure information, for further evaluation 
and diagnostic tests at the field clinic, fol-
lowed by treatment and referral to the only 
local hospital in the study area. All hospitaliza-
tions and records of standard diagnostic tests 
were requested and reviewed by the outcome 
assessment committee. Nonfatal stroke was 
defined based on WHO criteria as “rapidly 
developing clinical signs of focal disturbance 
of cerebral function, lasting > 24 hr with no 
apparent cause other than that of vascular ori-
gin” (Aho et al. 1980). Nonfatal ischemic heart 
disease was defined by meeting at least two of 
the three following criteria: a) ischemic cardiac 
pain determined to be typical angina, b) car-
diac enzyme abnormalities defined as abnormal 
CPK-MB fraction or troponin values (three 
times the upper limit of normal), and c) spe-
cific ST-T wave and Q wave electrocardio-
graphic abnormalities.
Arsenic exposure measurements. Total 
arsenic concentration was determined by 
graphite furnace atomic-absorption spectrom-
etry (GFAAS) with a Hitachi Z-8200 (Hitachi, 
Tokyo, Japan) system (Cheng et al. 2005). 
Samples that fell below the detection limit of 
5 µg/L were subsequently analyzed by induc-
tively coupled plasma mass spectrometry 
(ICP-MS), with a detection limit of 0.1 µg/L 
(Cheng et al. 2004). Analyses of time-series 
samples collected from 20 tube wells moni-
tored for 3 years in the study area showed that 
the arsenic concentration in well water was 
relatively stable over time (Cheng et al. 2005). 
We used the arsenic concentration in the 
index well assessed at baseline as the well-water 
arsenic exposure level. In the study population, 
88% of the study participants used the index 
well as their exclusive source of drinking water 
at baseline. The average duration of index well 
use was 7.4 years prior to baseline, accounting 
for ≥ 20% of each participant’s lifetime.
Spot urine samples were collected in 
50-mL acid-washed tubes from 95.6%, 
94.5%, and 91.2% of the cohort participants 
at baseline, the first follow-up, and second 
follow-up, respectively. Total urinary arsenic 
concentration was measured by GFAAS, using 
a PerkinElmer A Analyst 600 graphite furnace 
system (PerkinElmer, Waltham, MA, USA) 
(Nixon et al. 1991). Urinary creatinine was 
analyzed using a method based on the Jaffe 
reaction for adjustment of urinary total arsenic 
concentration (Slot 1965).
Measurement of urinary arsenic metabo-
lites. Urinary arsenic metabolites were ana-
lyzed using a method described by Reuter 
et al. (2003). This method employed high-
performance liquid chromatography separa-
tion of arsenobetaine (AsB), arsenocholine 
(AsC), AsV, AsIII, MMA, and DMA, followed 
by detection by ICP-MS using a dynamic 
reaction cell. The detection limits were 
0.2 µg/L for AsB and AsC, and 0.1 µg/L for 
all other metabolites. Because AsIII can oxi-
dize to AsV during sample transport, storage, 
and preparation, here we report total iAs (i.e., 
AsIII + AsV). iAs and MMA were undetect-
able in three and seven urine samples, respec-
tively. All the urine samples had detectable 
DMA. Measurements below the detection 
limit were assigned a value of 1/2 the detec-
tion limit. The percentage of iAs, MMA, and 
DMA in urine was calculated by dividing the 
concentration of each metabolite by the sum 
of the urinary concentrations of iAs, MMA, 
and DMA. We also constructed two methyla-
tion indices: a) the primary methyla tion 
index (PMI; the ratio of MMA to iAs), and 
b) the secondary methyla tion index (SMI; the 
ratio of DMA to MMA). The intraclass cor-
relations for urinary arsenic metabolites for 
3 months were all > 0.65, with the intraclass 
correlation estimates for MMA%, DMA%, 
and SMI all > 0.82.
Statistical analyses. We computed person-
years from baseline to the date of the first 
CVD event or the date of the third follow-
up visit. We estimated adjusted hazard ratios 
(aHRs) and their 95% confidence intervals 
(CIs) for CVD, stroke, and heart disease in 
relation to tertiles of baseline well-water arsenic 
and arsenic metabolite indices (iAs%, MMA%, 
DMA%, PMI, and SMI) determined in the 
sub cohort using Cox proportional hazards 
models with the survival and survey packages 
in R, version 2.13.1 (R Foundation, Vienna, 
Austria). The follow-up data for the subcohort 
(including those who developed disease) were 
treated as representative of the person-time 
experience of the overall cohort, and the data 
from controls in the subcohort were weighted 
by 1/10, the inverse of the sampling fraction 
from the source population (i.e., the 11,224 
participants in the full cohort who provided 
urine samples at baseline). The use of such 
weights allows the efficient use of subcohort 
data and data from cases not included in the 
subcohort (Barlow et al. 1999; Breslow et al. 
2009). Standard errors were estimated using 
the robust variance estimator proposed by 
Barlow (Barlow 1994; Barlow et al. 1999). 
We adjusted for CVD risk factors that might 
be related to the influence of arsenic exposure, 
including sex, age (years), body mass index 
(BMI; kilograms per meter squared), educa-
tional attainment (years), smoking status 
(never/ever), hypertension (systolic blood pres-
sure of ≥ 140 and/or diastolic blood pressure 
of ≥ 90 mmHg), and diabetes status (yes/no) 
at baseline (Chen Y et al. 2010). Age, BMI, 
and educational attainment were entered as 
continuous variables in the models. Potential 
confounders were selected by comparing 
models with and without each variable, and 
models with and without combinations of 
variables that had an impact on the associa-
tion of arsenic metabolite indices or well-water 
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arsenic with CVD risk. Subjects with missing 
data on BMI (n = 12) or hypertension (n = 9) 
were excluded, and a separate dummy variable 
was used for missing data on baseline diabetes 
status (n = 69) under a “missing at random” 
assumption. Additional adjustment for well-
water arsenic or total urinary arsenic did not 
materially change the effect estimates (data 
not shown). aHRs associated with well-water 
arsenic were additionally adjusted for change in 
urinary arsenic between visits, which was asso-
ciated with baseline well-water arsenic status 
and may be related to health effects. Natural 
cubic splines with two internal knots placed at 
the 33rd and 66th percentiles and boundary 
knots at the 5th and 95th percentiles were fit-
ted to estimate nonlinear associations between 
urinary MMA% and heart disease (Wahba 
1990; Wood 2006), with MMA% below the 
lower boundary knot used as the reference 
level of exposure. For the analyses pertain-
ing to heart disease, sensitivity analyses were 
conducted excluding disease categories other 
than ischemic heart disease (n = 27). Analyses 
excluding participants with arsenic metabolites 
under the detection limit (n = 10) generated 
nearly identical results (data not shown).
We explored the combined and single 
effects of urinary MMA%, DMA%, and SMI 
with key host characteristics (sex, age, BMI, 
and smoking status) and well-water arsenic 
on heart disease risk. We assessed the presence 
of synergy by testing whether the combined 
effect of arsenic exposure and a potential effect 
modifier was greater than the sum of their 
independent effects. We estimated relative 
excess risk for interaction (RERI) (Rothman 
and Greenland 1986) and its 95% CI using 
the standard delta method (Hosmer and 
Lemeshow 1992). RERI > 0 indicates the 
presence of synergy of two risk factors, and 
a 95% CI that is positive and excludes zero 
corresponds to p < 0.05 for RERI. aHRs for 
combined and single effects between SMI 
and other variables are not reported here 
because they were consistent with the results 
for MMA% and DMA%. All analyses were 
 conducted using R, version 2.13.1.
Results
A total of 369 cases of CVD were identified, 
including 211 cases of heart disease (68 fatal 
and 116 nonfatal cases of ischemic heart dis-
ease, and 27 deaths from other types of heart 
disease); 148 cases of stroke cases (91 fatal 
and 57 nonfatal cases); and 10 deaths due to 
pulmonary heart disease, hypertensive heart 
disease, or multiple valve diseases. Forty 
case participants were also included in the 
1,109-member subcohort, which was rep-
resentative of the overall cohort in terms of 
demographic, lifestyle, and arsenic exposure 
variables [see Supplemental Material, Table S1 
(http://dx.doi.org/10.1289/ehp.1205797)].
Cases of CVD were more likely to be men, 
older, and ever-smokers at baseline, compared 
to the subcohort (Table 1). Cases of CVD, and 
cases of heart disease specifically, had a higher 
education level and higher well-water arsenic 
at baseline. Cases of CVD, heart disease, and 
stroke were more likely to have diabetes, higher 
systolic blood pressure, and higher diastolic 
blood pressure at baseline. Compared with the 
subcohort members, cases had a lower average 
of urinary iAs% and SMI and a higher average 
of urinary MMA% and PMI.
We observed an increased risk of overall 
CVD and heart disease in participants with 
higher levels of baseline well-water arsenic. 
Participants exposed to ≥ 108 µg/L (mean, 
222.3 µg/L) of well-water arsenic were 
1.49 (95% CI: 1.06, 2.11) times and 1.54 
(95% CI: 1.02, 2.31) times more likely to 
develop CVD and heart disease, respectively, 
compared with their counterparts who were 
exposed to ≤ 25 µg/L (Table 2). The aHR 
for heart disease in association with a 1-SD 
increase in well-water arsenic (112 µg/L) was 
1.20 (95% CI: 1.04, 1.38). There was no sig-
nificant association between well-water arsenic 
and stroke risk, although the aHR associated 
with the highest level of well-water arsenic was 
elevated (aHR = 1.38; 95% CI: 0.84, 2.27).
A positive association was observed 
between urinary MMA% and CVD risk, 
with an aHR of 1.55 (95% CI: 1.08, 2.23) 
for the top tertile (Table 3). The aHRs for 
heart disease in increasing MMA% ter-
tiles were 1.00 (reference), 1.65 (95% CI: 
1.05, 2.60), and 1.61 (95% CI: 1.04, 2.49); 
however, the effect estimates did not suggest 
a linear dose–response relationship between 
urinary MMA% above the first tertile and 
risk of heart disease. Participants with mod-
erate DMA% (68.7–75.5%) had a signifi-
cantly reduced heart disease risk. A similar 
but nonsignificant association was observed 
between high DMA% and heart disease risk. 
Participants with an SMI ≥ 7.2 had a statis-
tically significant reduction in risk of CVD 
and heart disease (aHR = 0.54; 95% CI: 
0.34, 0.85 and aHR = 0.54; 95% CI: 
Table 1. Baseline characteristics of subcohort members and participants with incident CVD.a
Characteristic CVDb Heart diseaseb Strokeb Subcohort
Participants (n) 369 211 148 1,109
Male (%) 74.0 70.6 77.7 42.9
Age (years) 48.5 ± 9.3 46.3 ± 9.5 51.5 ± 8.4 37.1 ± 10.1
BMI (kg/m2) 20.1 ± 3.7 20.7 ± 4.0 19.4 ± 3.2 19.9 ± 3.4
Education level (years) 3.9 ± 4.2 4.3 ± 4.3 3.2 ± 4.0 3.5 ± 3.8
Cigarette smoking status (%)
Ever-smokers in men 88.6 88.6 89.6 76.9
Ever-smokers in women 19.8 24.2 12.1 6.8
Systolic blood pressure (mmHg) 130.7 ± 26.5 126.4 ± 24.2 137.6 ± 28.8 114.4 ± 17.5
Diastolic blood pressure (mmHg) 81.7 ± 14.7 80.2 ± 13.3 84.5 ± 16.3 74.1 ± 11.5
Diabetes status (%) 7.5 5.7 9.9 2.1
Well-water arsenic (µg/L) 104.2 ± 113.8 110.5 ± 123.4 95.5 ± 100.4 96.4 ± 111.7
Total urinary arsenic (µg/g creatinine) 259.9 ± 235.7 268.0 ± 247.5 249.4 ± 220.6 277.1 ± 356.3
Urinary iAs% 14.3 ± 6.1 14.5 ± 6.1 14.1 ± 6.2 15.9 ± 7.1
Urinary MMA% 14.4 ± 5.3 14.5 ± 5.4 14.3 ± 5.3 12.8 ± 5.1
Urinary DMA% 71.3 ± 8.1 71.0 ± 8.6 71.7 ± 7.6 71.3 ± 8.9
PMI [MMA/(AsIII + AsV)] 1.2 ± 0.6 1.2 ± 0.6 1.2 ± 0.7 1.0 ± 0.8
SMI (DMA/MMA) 5.8 ± 2.9 5.8 ± 3.1 5.8 ± 2.7 6.7 ± 3.6
Abbreviations: PMI, primary methyla tion index; SMI, secondary methyla tion index. Values are mean ± SD except where 
indicated.
aData on BMI, systolic blood pressure, diastolic blood pressure, and diabetes status were missing for 12, 9, 9, and 105 
participants, respectively. bCVD cases include incident fatal and nonfatal cases of CVD (ICD-10 codes I00–I99); cases of 
heart disease include fatal and nonfatal cases of ischemic heart disease and deaths from other heart disease (codes 
I20–I25 and I30–I52); stroke cases include fatal and nonfatal stroke (I60–I69); 10 deaths due to pulmonary heart disease, 
hyper tensive heart disease, or multiple valve diseases were not classified as heart disease or stroke cases.
Table 2. Association between baseline well-water arsenic (μg/L) and CVD risk.
Well-water arsenic (μg/L) Meana Subcohort (n)
CVD Heart disease Stroke
Cases (n) aHR (95% CI)b Cases (n) aHR (95% CI)b Cases (n) aHR (95% CI)b
0.1–25 7.2 365 114 1.00 61 1.00 50 1.00
25.1–107 59.9 364 120 1.00 (0.67, 1.50) 72 1.18 (0.75, 1.84) 46 0.86 (0.49, 1.51)
108–864 222.8 364 132 1.49 (1.06, 2.11) 75 1.54 (1.02, 2.31) 52 1.38 (0.84, 2.27)
Per 1 SD (112 μg/L) increase 1,093 366 1.15 (1.01, 1.30) 208 1.20 (1.04, 1.38) 148 1.08 (0.90, 1.30)
aCategory-specific mean values of well-water arsenic in the subcohort. bAdjusted for sex, baseline age, BMI, smoking status (never and ever), educational attainment, hypertension, 
diabetes status, and change in urinary arsenic between visits.
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0.33, 0.88, respectively), compared with those 
who had an SMI ≤ 4.8. On the other hand, 
there was no significant association of iAs% 
or PMI with CVD or heart disease. There was 
no evidence that iAs%, MMA%, DMA%, 
PMI, or SMI were related to stroke risk, 
with the possible exception of a nonsignifi-
cant negative association between stroke and 
SMI ≥ 7.2 (aHR = 0.58; 95% CI: 0.31, 1.08). 
Well-water arsenic and total urinary arsenic 
were weakly correlated with MMA%, with a 
Spearman rank correlation of 0.10 and 0.07, 
respectively. The associations for ischemic 
heart disease only (n = 184 after excluding 
27 deaths due to nonischemic heart disease) 
were similar to those for all heart disease cases. 
For instance, the aHRs for increasing MMA% 
tertiles were 1.00 (reference), 1.68 (95% CI: 
1.04, 2.72), and 1.64 (95% CI: 1.03, 2.59).
We further explored the nonlinear associa-
tion between urinary MMA% and heart disease 
risk. The data suggested a nonlinear association 
(Figure 1), such that the log aHRs for heart dis-
ease increased with increasing urinary MMA% 
through the first third of the distribution, but 
leveled off for higher levels of MMA%.
Compared with younger persons with 
lower MMA%, heart disease risk among 
those who were older and had higher MMA% 
(aHR = 3.88; 95% CI: 2.12, 7.09) was greater 
than that among those who were older and 
had a lower MMA% (aHR = 2.85; 95% CI: 
1.53, 5.31) (Table 4). Compared with never-
smokers with lower MMA%, heart disease risk 
among ever-smokers who had higher MMA% 
(aHR = 3.82; 95% CI: 2.04, 7.14) was greater 
than that among ever-smokers who had lower 
MMA% (aHR = 2.58; 95% CI: 1.30, 5.11). 
The pattern of the associations was similar 
when DMA% was considered. The com-
bined effects of higher MMA% and lower 
DMA% with older age and ever-smoking 
were greater than the sum of the individual 
effects (all RERI > 0), indicating synergistic 
effects; however, the estimates were not pre-
cise and not statistically significant. There 
was no apparent synergistic effect of sex and 
BMI with higher MMA% or lower DMA% 
[see Supplemental Material, Table S2 (http://
dx.doi.org/10.1289/ehp.1205797)]. At each 
level of well-water arsenic, heart disease risk 
was higher among those with higher MMA% 
or lower DMA% (Figure 2). Compared with 
participants with the lowest level of well-
water arsenic and lower MMA% (≤ 12%), 
those with moderate (25.1–107 µg/L) or high 
levels of well-water arsenic (108–864 µg/L) 
were more likely to develop heart disease, 
and partici pants exposed to high levels of 
Table 3. Associations between urinary arsenic metabolite indices and CVD risk.
Urinary arsenic 
metabolic index Meana Subcohort (n)
CVD Heart disease Stroke
Cases (n) aHR (95% CI)b Cases (n) aHR (95% CI)b Cases (n) aHR (95% CI)b
iAs%c
0.3–12.4 9.3 363 157 1.00 92 1.00 63 1.00
12.5–17.3 14.8 367 118 1.28 (0.90, 1.81) 60 1.12 (0.74, 1.68) 53 1.39 (0.84, 2.29)
17.4–69.3 23.2 363 91 1.05 (0.71, 1.56) 56 1.17 (0.76, 1.80) 32 0.87 (0.49, 1.57)
MMA%c
0.2–10.3 7.7 366 74 1.00 40 1.00 32 1.00
10.4–14.3 12.3 363 131 1.27 (0.85, 1.90) 81 1.65 (1.05, 2.60) 49 0.91 (0.51, 1.61)
14.4–33.8 18.6 364 161 1.55 (1.08, 2.23) 87 1.61 (1.04, 2.49) 67 1.35 (0.81, 2.27)
DMA%c
27.9–68.6 61.6 363 117 1.00 74 1.00 39 1.00
68.7–75.5 72.1 367 133 0.98 (0.69, 1.39) 65 0.65 (0.43, 0.98) 64 1.53 (0.91, 2.55)
75.6–99.2 80.2 363 116 0.75 (0.49, 1.14) 69 0.68 (0.44, 1.05) 45 0.90 (0.48, 1.67)
PMIc
0.01–0.66 0.48 362 83 1.00 48 1.00 34 1.00
0.67–1.05 0.85 365 98 0.93 (0.65, 1.34) 56 0.91 (0.59, 1.39) 37 0.88 (0.52, 1.51)
1.06–19.57 1.61 363 185 0.88 (0.61, 1.26) 104 0.91 (0.59, 1.40) 77 0.81 (0.49, 1.34)
SMIc
1.4–4.8 3.6 361 152 1.00 88 1.00 59 1.00
4.9–7.1 5.9 363 136 1.00 (0.72, 1.38) 77 1.02 (0.70, 1.48) 56 1.00 (0.61, 1.64)
7.2–32.3 10.5 363 77 0.54 (0.34, 0.85) 43 0.54 (0.33, 0.88) 32 0.58 (0.31, 1.08)
Abbreviations: PMI, primary methyla tion index; SMI, secondary methyla tion index.
aCategory-specific mean values of urinary arsenic metabolites in the subcohort. bAdjusted for sex, baseline age (years), BMI, smoking status (never and ever), educational attainment, 
hypertension, and diabetes status. cCut points were determined by tertiles in the subcohort.
Figure 1. Log aHRs for incident heart disease according to urinary MMA% modeled as a natural cubic 
spline with internal knots placed at the 33rd and 66th percentiles and boundary knots at the 5th and 95th 
percentiles adjusted for sex, baseline age (years), BMI, smoking status (never and ever), educational 
attainment, hypertension, and diabetes status. The ticks at the bottom represent urinary MMA% values 
and the dashed black vertical lines represent the location of knots used for fitting the cubic spline. The 
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arsenic and also had higher MMA% or lower 
DMA% were most likely to develop heart dis-
ease (aHR = 2.17 and 1.82, respectively). The 
RERI for synergistic effect between well-water 
arsenic and higher MMA% was 0.05 (95%CI: 
–1.25, 1.36) at moderate levels of well-water 
arsenic and was –0.29 (95% CI: –1.73, 1.14) 
at high levels of well-water arsenic. The RERI 
for synergistic effect between well-water 
arsenic and lower DMA% was 0.28 (95% CI: 
–0.76, 1.31) and 0.16 (95% CI: –0.95, 1.26) 
at moderate and high levels of well-water 
arsenic, respectively.
Discussion
In this prospective study, we found an 
increased risk of fatal and nonfatal CVD, 
especially heart disease, associated with higher 
well-water arsenic concentration and lower 
methyla tion capacity, indicated by higher uri-
nary MMA% or lower DMA%. We observed 
that the association between urinary MMA% 
and heart disease was nonlinear, such that the 
association increased with increasing MMA% 
at lower levels, and then appeared to level 
off. The effects associated with higher levels 
of well-water arsenic and lower methyla tion 
capacity on heart disease risk were at least 
additive. There was some evidence of a small 
synergistic effect between lower methyla tion 
capacity and older age or cigarette smoking, 
although the estimates were imprecise.
We have previously reported a significant 
positive association between arsenic expo-
sure at moderate-to-high levels (> 100 µg/L) 
and CVD mortality, especially heart dis-
ease mortality in the population, with 198 
CVD deaths (Chen Y et al. 2011). The pres-
ent study adds to the evidence supporting a 
causal relation between arsenic exposure and 
heart disease with findings supported by a 
much larger sample size with 369 fatal and 
nonfatal CVD cases. In our data, the asso-
ciation between arsenic exposure and stroke 
risk was not significant. This finding was 
in line with two previous ecological studies 
of high levels (> 300 µg/L) of arsenic expo-
sure (Wu et al. 1989; Yuan et al. 2007) but 
not with a cross-sectional study of moder-
ate levels (median < 140 µg/L in various vil-
lages) (Chiou et al. 1997). Importantly, in 
the present study, we also found a positive 
association between urinary MMA%—a bio-
marker specific for susceptibility to the health 
effects of arsenic exposure—and heart disease 
risk, and the association between MMA% 
and stroke risk was weaker and nonsignifi-
cant, suggesting the effect of arsenic exposure 
on heart disease risk was stronger than that 
on stroke risk. However, stroke is a hetero-
geneous disease that comprises subtypes with 
different etiologies, and future studies that 
estimate associations for subtypes of stroke are 
needed. It should be noted that our study is 
mostly informative and supportive of cardio-
vascular effects at moderate-to-high levels 
of arsenic exposure (> 100 µg/L). Findings 
from studies of lower levels of arsenic expo-
sure (< 100 µg/L) from drinking water have 
been inconsistent (Engel and Smith 1994; 
Medrano et al. 2010; Meliker et al. 2007), 
possibly because of limitations such as narrow 
exposure ranges and measurement errors.
Previous studies have reported evidence of 
adverse effects of incomplete arsenic methyla-
tion capacity on cancer risk. The literature 
on the role of arsenic methyla tion capacity in 
the risk of stroke and heart disease is limited. 
Tseng et al. (2005) reported that among indi-
viduals with high arsenic exposure, the preva-
lence of peripheral vascular disease was greater 
among those with higher levels of MMA%. 
In studies of hypertension and carotid athero-
sclerosis from the same population, there was 
an insignificant positive association of urinary 
MMA% with the prevalence of hyper tension 
and carotid athero sclerosis (Huang YK et al. 
2007; Huang YL et al. 2009). In the present 
study, we also observed a significant inverse 
association between SMI (the ratio of DMA 
to MMA) and the risk of CVD and heart 
disease. There was no evidence that iAs% or 
PMI was related to CVD risk. These data 
suggest a more critical role of the second 
methyla tion step, or of complete methyla-
tion capacity, than the first step in arsenic 
methyla tion. In addition, compared with par-
ticipants with the lowest level of well-water 
Table 4. Estimated combined effects of urinary metabolite indices and baseline age and smoking status on heart disease risk.
Urinary arsenic 
metabolite index
Combined effect between urinary arsenic metabolite indices and age Combined effect between urinary arsenic metabolite indices and smoking
Agea Cases/subcohort (n) aHR (95% CI)b RERI (95% CI) Smoking status Cases/subcohort (n) aHR (95% CI)c RERI (95% CI)
MMA%a
≤ 12.4 ≤ 36 15/305 1.00 Never 35/392 1.00
> 12.4 ≤ 36 13/255 0.94 (0.43, 2.01) Never 28/295 1.29 (0.75, 2.20)
≤ 12.4 > 36 61/244 2.85 (1.53, 5.31) Ever 41/157 2.58 (1.30, 5.11)
> 12.4 > 36 119/289 3.88 (2.12, 7.09) 1.09 (–0.28, 2.47) Ever 104/249 3.82 (2.04, 7.14) 0.96 (–0.63, 2.55)
DMA%a
> 72.2 ≤ 36 11/282 1.00 Never 38/374 1.00
≤ 72.2 ≤ 36 17/278 1.41 (0.64, 3.07) Never 25/313 1.25 (0.73, 2.15)
> 72.2 > 36 96/263 3.67 (1.81, 7.43) Ever 69/171 2.81 (1.56, 5.05)
≤ 72.2 > 36 84/270 4.99 (2.53, 9.83) 0.92 (–0.83, 2.66) Ever 76/235 3.93 (2.14, 7.22) 0.88 (–0.81, 2.56)
aCut points were determined by median values in the subcohort. bAdjusted for sex, baseline BMI, smoking status (never and ever), educational attainment, hypertension, and diabetes 
status. cAdjusted for sex, baseline age (years), BMI, educational attainment, hypertension, and diabetes status.
Figure 2. Estimated combined effects (aHRs and 95% CIs) of urinary MMA% and DMA% with well-water 
arsenic on heart disease risk, adjusted for sex, baseline age (years), BMI, smoking status (never and ever), 
educational attainment, hypertension, diabetes status, and change in urinary arsenic between visits.
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arsenic and higher methyla tion capacity, 
those exposed to moderate or high levels of 
well-water arsenic and who also had lower 
methyla tion capacity were most likely to 
develop heart disease (Figure 2). The data 
suggest a potential synergy between arsenic 
exposure and lower methyla tion capacity at 
moderate but not high levels of arsenic expo-
sure. However, the estimates were imprecise. 
Collectively, data from the present study and 
previous studies suggest that individuals with 
suboptimal or incomplete arsenic methyla-
tion capacity are more susceptible to adverse 
effects of arsenic exposure, including effects 
on both cancer and CVD. Future studies are 
needed to assess whether the susceptibility 
due to lower methyla tion capacity was more 
critical at lower levels of exposure.
We found that the association between 
MMA% and heart disease risk was slightly 
stronger in ever-smokers compared with 
never-smokers, although the differences 
were not significant. This finding suggests 
that arsenic methyla tion capacity is likely to 
explain partly the synergy between arsenic 
exposure and smoking in heart disease risk, 
as observed in our previous cohort analyses 
on CVD mortality (Chen Y et al. 2011). 
Several studies have documented a synergistic 
effect of MMA% and smoking in the risk of 
bladder cancer (Steinmaus et al. 2006) and 
urothelial carcinoma (Pu et al. 2007). Taken 
together, the body of literature suggests that 
cigarette smoking may be an important factor 
that influences the health effects of arsenic 
exposure and arsenic methyla tion capacity.
The mechanisms by which arsenic leads 
to heart disease still remain to be elucidated. 
Several animal studies have suggested that 
arsenic can induce athero sclerosis (Cheng 
et al. 2011; Lemaire et al. 2011; Simeonova 
et al. 2003; Srivastava et al. 2009) and high 
blood pressure (Sanchez-Soria et al. 2012), 
possibly by induction of oxidative stress, 
inflammatory responses, and endothelial dys-
function as reviewed by Navas-Acien et al. 
(2005). Epidemiologic studies have suggested 
that arsenic may increase heart disease risk 
through its effects on subclinical cardio-
vascular outcomes, as evidenced by the posi-
tive associations of arsenic exposure with the 
prevalence of QTc prolongation (Chen Y et al. 
2013b; Mordukhovich et al. 2009; Mumford 
et al. 2007) and subclinical anthrosclerosis 
(Chen Y et al. 2013a; Wang et al. 2002). 
Future studies on effects of arsenic on preclini-
cal phenotypes relevant for heart disease are 
needed to clarify the underlying mechanisms.
Several aspects should be taken into 
 consideration when interpreting the results of 
our study:
•	Although participants had on average used 
the baseline wells for 7.4 years, we did not 
have a complete history of lifetime exposure, 
and some participants did not use the base-
line well exclusively. Changes in exposure 
level since baseline also occurred in some 
participants (Chen Y et al. 2007). The 
potential misclassification of exposure is 
probably unlikely to be differential by sub-
sequent disease status. However we could 
not estimate the extent of the potential 
measurement errors. 
•	We were unable to distinguish and quantify 
MMAIII and MMAV separately in urine. 
MMAIII is very unstable and must be mea-
sured or stabilized immediately after collec-
tion, making it impractical for this study 
design (Valenzuela et al. 2005). 
•	Urinary arsenic metabolites were measured 
in one spot urine sample. The literature sug-
gests that arsenic methyla tion efficiency of an 
individual is stable over time (Concha et al. 
2002; Navas-Acien et al. 2009). However, 
we were not able to estimate the effects of 
arsenic metabolites at different time periods 
or during specific time windows, nor could 
we estimate the latency of associations. 
•	CVD deaths were ascertained using the ver-
bal autopsy procedure, which may involve 
some misclassification. We might also have 
missed some nonfatal cases because the 
ascertainment relies partly on participant 
visits to the field clinic. However, there was 
no evidence that factors related to access 
to health care, such as socioeconomic vari-
ables including occupation, education, and 
land ownership were associated with arsenic 
exposure levels in the cohort (Chen Y et al. 
2010). Although we believe that potential 
misclassification of CVD deaths and incom-
plete ascertainment of nonfatal cases was 
unlikely to have been differential by arsenic 
levels, we cannot predict the exact direction 
or extent of the potential bias with certainty. 
•	Finally, although we did not collect infor-
mation on lipid profiles at baseline, avail-
able literature does not suggest a positive 
association between arsenic exposure and 
lipid profiles, nor was there evidence that 
the association between arsenic exposure 
and CVD is modifiable by lipid profiles 
(Simeonova et al. 2003; Tseng et al. 1997).
Conclusions
We observed a positive association of arsenic 
exposure from drinking water and the pro-
portion of MMA in urine with the risk of 
CVD, especially heart disease. The risk of 
heart disease associated with higher levels of 
arsenic exposure and incomplete methyla tion 
capacity, indicated by higher urinary MMA% 
or lower urinary DMA%, was greater than 
the risk associated with the same levels of 
arsenic but better methyla tion capacity. The 
data also suggest a possible synergy between 
incomplete methyla tion and older age, and 
between incomplete methyla tion capacity 
and cigarette smoking, although the estimates 
were not precise. These findings stress that 
arsenic methyla tion capacity is a susceptible 
factor for the cardio vascular effects of arsenic 
exposure.
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